PL3321287T3 - Białka fuzyjne oraz szczepionki skojarzone - Google Patents

Białka fuzyjne oraz szczepionki skojarzone

Info

Publication number
PL3321287T3
PL3321287T3 PL17201766T PL17201766T PL3321287T3 PL 3321287 T3 PL3321287 T3 PL 3321287T3 PL 17201766 T PL17201766 T PL 17201766T PL 17201766 T PL17201766 T PL 17201766T PL 3321287 T3 PL3321287 T3 PL 3321287T3
Authority
PL
Poland
Prior art keywords
fusion proteins
combination vaccines
vaccines
combination
fusion
Prior art date
Application number
PL17201766T
Other languages
English (en)
Inventor
Normand Blais
Steve Labbe
Jan Poolman
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47008755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3321287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL3321287T3 publication Critical patent/PL3321287T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17201766T 2011-04-13 2012-04-12 Białka fuzyjne oraz szczepionki skojarzone PL3321287T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161474779P 2011-04-13 2011-04-13
US201161534012P 2011-09-13 2011-09-13
EP12771540.7A EP2707393B1 (en) 2011-04-13 2012-04-12 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
PCT/CA2012/050236 WO2012139225A1 (en) 2011-04-13 2012-04-12 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
EP17201766.7A EP3321287B1 (en) 2011-04-13 2012-04-12 Fusion proteins & combination vaccines

Publications (1)

Publication Number Publication Date
PL3321287T3 true PL3321287T3 (pl) 2020-07-27

Family

ID=47008755

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12771540T PL2707393T3 (pl) 2011-04-13 2012-04-12 Białka fuzyjne oraz szczepionki skojarzone zawierające białko e i pilinę a haemophilus influenzae
PL17201766T PL3321287T3 (pl) 2011-04-13 2012-04-12 Białka fuzyjne oraz szczepionki skojarzone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12771540T PL2707393T3 (pl) 2011-04-13 2012-04-12 Białka fuzyjne oraz szczepionki skojarzone zawierające białko e i pilinę a haemophilus influenzae

Country Status (36)

Country Link
US (7) US8945577B2 (pl)
EP (2) EP3321287B1 (pl)
JP (1) JP6196963B2 (pl)
KR (1) KR101999673B1 (pl)
CN (3) CN103476799A (pl)
AR (1) AR086078A1 (pl)
AU (1) AU2012243412C1 (pl)
BR (1) BR112013026175B1 (pl)
CA (1) CA2830786C (pl)
CL (1) CL2013002937A1 (pl)
CO (1) CO6781540A2 (pl)
CR (1) CR20130529A (pl)
CY (2) CY1120319T1 (pl)
DK (2) DK2707393T3 (pl)
DO (1) DOP2013000235A (pl)
EA (1) EA031580B1 (pl)
ES (2) ES2658512T3 (pl)
HR (2) HRP20180216T1 (pl)
HU (2) HUE036983T2 (pl)
IL (2) IL271862B (pl)
LT (2) LT2707393T (pl)
MA (1) MA35110B1 (pl)
ME (1) ME02995B (pl)
MX (1) MX350013B (pl)
PE (1) PE20140986A1 (pl)
PH (1) PH12013502121A1 (pl)
PL (2) PL2707393T3 (pl)
PT (2) PT3321287T (pl)
RS (1) RS56903B1 (pl)
SG (2) SG193906A1 (pl)
SI (2) SI2707393T1 (pl)
SM (1) SMT201800125T1 (pl)
TW (1) TW201302779A (pl)
UY (1) UY34017A (pl)
WO (1) WO2012139225A1 (pl)
ZA (1) ZA201307118B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
EA201590491A1 (ru) * 2012-10-17 2016-01-29 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
WO2015042723A1 (en) 2013-09-30 2015-04-02 Iaf Science Holdings Ltd. Chewable product and process for making same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2016115522A2 (en) * 2015-01-16 2016-07-21 University Of Kentucky Research Foundation Lipid bilayer-integrated spp1 connector protein nanopore and spp1 connector protein variants for use as lipid bilayer-integrated nanopore
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
EP3600391A1 (en) * 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3641808A1 (en) * 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
CN107602697B (zh) * 2017-08-29 2020-05-05 杭州医学院 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
US12076352B2 (en) * 2018-06-19 2024-09-03 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN110540598B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
WO2020174044A1 (en) 2019-02-27 2020-09-03 Evaxion Biotech Aps Vaccines targeting h. influenzae
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112021026775A2 (pt) 2019-08-05 2022-05-10 Glaxosmithkline Biologicals Sa Processo para preparar uma composição que compreende um polipeptídeo de proteína d
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production
CN116621952A (zh) * 2022-09-16 2023-08-22 山东滨州沃华生物工程有限公司 B型副鸡禽杆菌抗原PilA蛋白及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69033600T2 (de) * 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002028889A2 (en) 2000-10-02 2002-04-11 Shire Biochem Inc. Haemophilus influenzae antigens and corresponding dna fragments
US6942802B2 (en) 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
ATE534900T1 (de) 2003-07-09 2011-12-15 Life Technologies Corp Verfahren zum testen einer protein-protein- wechselwirkung
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
PE20061441A1 (es) * 2005-05-12 2007-01-18 Novartis Ag Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
BRPI0613593A2 (pt) * 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
ATE488526T1 (de) 2005-07-08 2010-12-15 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae- induzierte infektion
EA014352B1 (ru) 2005-08-10 2010-10-29 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
MY150105A (en) * 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Also Published As

Publication number Publication date
CY1120319T1 (el) 2019-07-10
PE20140986A1 (es) 2014-08-20
EP2707393A1 (en) 2014-03-19
NZ615328A (en) 2015-10-30
TW201302779A (zh) 2013-01-16
PT2707393T (pt) 2018-02-09
ES2776369T3 (es) 2020-07-30
AU2012243412C1 (en) 2015-12-10
BR112013026175B1 (pt) 2020-05-12
ME02995B (me) 2018-10-20
PT3321287T (pt) 2020-05-22
HUE036983T2 (hu) 2018-08-28
SI2707393T1 (en) 2018-03-30
US20140056934A1 (en) 2014-02-27
KR101999673B1 (ko) 2019-07-12
CA2830786C (en) 2021-10-26
EA201391240A1 (ru) 2014-04-30
US10023616B2 (en) 2018-07-17
US20160250313A1 (en) 2016-09-01
RS56903B1 (sr) 2018-05-31
US11198707B2 (en) 2021-12-14
MA35110B1 (fr) 2014-05-02
US20170029472A1 (en) 2017-02-02
US20180222946A1 (en) 2018-08-09
US8945577B2 (en) 2015-02-03
CA2830786A1 (en) 2012-10-18
US10214569B2 (en) 2019-02-26
EP2707393A4 (en) 2014-11-05
WO2012139225A1 (en) 2012-10-18
DK3321287T3 (da) 2020-05-04
CO6781540A2 (es) 2013-10-31
HRP20200466T1 (hr) 2020-06-26
KR20140026483A (ko) 2014-03-05
EP2707393B1 (en) 2017-12-20
CY1122824T1 (el) 2021-05-05
DOP2013000235A (es) 2014-03-16
IL271862B (en) 2022-07-01
SG193906A1 (en) 2013-11-29
AU2012243412A1 (en) 2013-04-18
DK2707393T3 (da) 2018-01-29
AU2012243412B2 (en) 2015-05-14
JP6196963B2 (ja) 2017-09-13
US10730917B2 (en) 2020-08-04
SG10201602549WA (en) 2016-05-30
CN103476799A (zh) 2013-12-25
PL2707393T3 (pl) 2018-05-30
US20200331972A1 (en) 2020-10-22
HRP20180216T1 (hr) 2018-03-09
EA031580B1 (ru) 2019-01-31
ZA201307118B (en) 2022-03-30
SMT201800125T1 (it) 2018-05-02
IL228344A0 (en) 2013-12-31
AR086078A1 (es) 2013-11-20
LT3321287T (lt) 2020-06-10
EP3321287A1 (en) 2018-05-16
PH12013502121A1 (en) 2014-01-13
HUE048848T2 (hu) 2020-08-28
UY34017A (es) 2012-11-30
US20150175670A1 (en) 2015-06-25
CN107383201A (zh) 2017-11-24
EP3321287B1 (en) 2020-02-26
MX2013011939A (es) 2014-03-27
IL228344B (en) 2020-01-30
LT2707393T (lt) 2018-03-12
IL271862A (en) 2020-02-27
CL2013002937A1 (es) 2014-07-25
ES2658512T3 (es) 2018-03-12
US9409957B2 (en) 2016-08-09
BR112013026175A2 (pt) 2016-11-29
CN107522788A (zh) 2017-12-29
MX350013B (es) 2017-08-23
US20150166613A1 (en) 2015-06-18
SI3321287T1 (sl) 2020-07-31
CR20130529A (es) 2014-03-05
US9296794B2 (en) 2016-03-29
JP2014512365A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
LT3321287T (lt) Sulieti baltymai ir sudėtinės vakcinos
SG11201400432VA (en) Polypeptide vaccine
ZA201404667B (en) Anticancer fusion protein
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
GB201101140D0 (en) Fused aminodihydrothiazine derivatives
EP2772230A4 (en) FUSION GRAFT
SG10202100341XA (en) Npp1 fusion proteins
ZA201309399B (en) Peptide carrier fusion proteins as allergy vaccines
SI2661496T1 (sl) Fuzijski protein proti raku
ZA201405460B (en) Anticancer fusion protein
EP2698386B8 (en) Fusion protein
EP2657337A4 (en) FUSION PROTEIN
PL2622078T3 (pl) Białko fuzyjne dla ekspresji białka wydzielniczego
ZA201308597B (en) Anticancer fusion protein
ZA201306245B (en) Combination vaccines
PT2744831T (pt) Proteína de fusão de transferrina-tumstatina e métodos para a produzir e utilizar
ZA201207425B (en) Fusion protein
GB201107189D0 (en) Fusion proteins
GB201114701D0 (en) Fusion proteins
GB201104152D0 (en) Fusion Polypeptide
GB201007955D0 (en) Somatosatin fusion proteins
AU4710P (en) Fusion xTriticosecale
GB201204065D0 (en) Fusion polypeptide
AU2011905145A0 (en) Fusion Protein
GB201108982D0 (en) Vaccines